Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketanserin is an antihypertensive agent primarily used to treat arterial hypertension and vasospastic disorders. It acts as a high-affinity, non-selective antagonist of serotonin 5-HT2 receptors (notably 5-HT2A) and also exhibits antagonistic activity at histamine H1 receptors and weak alpha 1-adrenoceptor blocking properties. Ketanserin inhibits serotonin-induced vasoconstriction, platelet activation, and aggregation, leading to reduced systemic vascular resistance and improved vascular compliance. It has been shown to lower blood pressure—especially in older adults—and improve microcirculation in conditions such as Raynaud's disease and scleroderma-related ulcers. Ketanserin is also used in scientific research for its antiserotonergic effects on the serotonin system[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketanserin.